Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been assigned an average recommendation of "Buy" from the ten ratings firms that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $40.38.

A number of equities research analysts have recently commented on ORKA shares. Wall Street Zen raised shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. BTIG Research started coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating for the company. Finally, Wedbush restated an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Thursday, May 15th.

Oruka Therapeutics Trading Down 4.6%

ORKA traded down $0.55 during trading on Monday, reaching $11.31. 108,294 shares of the company's stock were exchanged, compared to its average volume of 224,037. Oruka Therapeutics has a one year low of $5.49 and a one year high of $31.13. The stock has a market capitalization of $423.27 million, a PE ratio of -1.79 and a beta of 0.25. The firm has a fifty day moving average price of $9.74 and a two-hundred day moving average price of $13.87.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Sell-side analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ORKA. China Universal Asset Management Co. Ltd. bought a new stake in Oruka Therapeutics in the fourth quarter valued at $144,000. AlphaCentric Advisors LLC purchased a new stake in Oruka Therapeutics during the 4th quarter valued at approximately $119,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at $303,000. Vanguard Group Inc. lifted its position in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in shares of Oruka Therapeutics during the fourth quarter worth $54,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.